Azitra, Inc. has recently filed an amendment to its Schedule 13G, which details changes in the ownership of its shares by key investors. This filing is significant as it reflects the growing interest from institutional investors in the pharmaceutical preparations sector.

As of November 12, 2026, the filing reveals that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri collectively own 1,344,308 shares of Azitra, representing approximately 2.22% of the company's common stock. The filing indicates that these shares are related to certain warrants held by the reporting persons.

Background

Azitra, Inc. is a company based in Branford, Connecticut, classified under the SIC code 2834, which pertains to pharmaceutical preparations. The company trades on the New York Stock Exchange under the ticker symbol AZTR. Azitra has been active in the pharmaceutical sector, focusing on developing innovative therapies.

What the Filing Says

The Schedule 13G/A filing states, "The shares reported herein represent Common Stock of Azitra, Inc. held by the Reporting Persons." It also notes that the reporting persons have sole voting and dispositive power over the shares they hold.

Impact

This filing may affect the perception of Azitra among investors and analysts, as it highlights the involvement of significant investment entities. The presence of institutional investors like Ayrton Capital and Alto Opportunity Master Fund could signal confidence in Azitra's future prospects, potentially influencing other investors in the pharmaceutical preparations sector.

What's Next

The filing does not say what happens next.